How OJJAARA works

OJJAARA is a type of medicine called a Janus kinase (JAK) inhibitor.

What are JAKs?

Janus kinases (JAKs) are proteins that can be found inside certain cells, including stem cells located in the bone marrow.

Normal bone marrow stem cell
Divider with icon
Divider with icon

The role of JAKs in myelofibrosis

In myelofibrosis, the DNA in normal bone marrow cells changes. This DNA mutation may cause JAKs to become overactive. As myelofibrosis progresses, there is more JAK overactivity.

Researchers believe these abnormal bone marrow stem cells cause inflammation that may lead to a buildup of scar tissue inside the bone marrow. The formation of this scar tissue, known as fibrosis, replaces some of the normal bone marrow, leading to a decreased production of normal blood cells.

Abnormal bone marrow stem cell
Divider with icon
Divider with icon

How does OJJAARA work?

OJJAARA is believed to work by binding to, and inhibiting, the activity of overactive JAKs.

OJJAARA binds to JAK protein
Divider with icon
Divider with icon

OJJAARA also inhibits ACVR1

In addition to inhibiting JAK proteins, OJJAARA inhibits a signal from another protein called activin A receptor type 1, or ACVR1, in your liver cells. This can result in an increase in your number of red blood cells.

OJJAARA binds to ACVR1
Ask your doctor about OJJAARA

OJJAARA is the first and only FDA-approved treatment specifically for adults with certain types of myelofibrosis (MF) who have anemia.